Peter Rossing Selected Research

Diabetic Nephropathies (Diabetic Nephropathy)

6/2022	Precision diagnostic approach to predict 5-year risk for microvascular complications in type 1 diabetes.
1/2022	Urinary Proteomics Identifies Cathepsin D as a Biomarker of Rapid eGFR Decline in Type 1 Diabetes.
1/2022	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
1/2022	Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
1/2022	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
1/2022	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
1/2022	Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.
12/2021	Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial.
7/2021	Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial.
1/2021	Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Rossing Research Topics

Disease

134	Type 2 Diabetes Mellitus (MODY) 07/2022 - 03/2004
90	Albuminuria 06/2022 - 07/2002
89	Diabetic Nephropathies (Diabetic Nephropathy) 06/2022 - 07/2002
67	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/2022 - 05/2002
67	Chronic Renal Insufficiency 06/2022 - 07/2008
44	Cardiovascular Diseases (Cardiovascular Disease) 04/2022 - 10/2004
32	Heart Failure 01/2022 - 03/2012
27	Chronic Kidney Failure (Chronic Renal Failure) 10/2021 - 09/2004
23	Kidney Diseases (Kidney Disease) 04/2022 - 07/2009
23	Renal Insufficiency (Renal Failure) 03/2022 - 05/2019
22	Inflammation (Inflammations) 06/2022 - 12/2006
15	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 11/2010
13	Disease Progression 06/2022 - 07/2008
12	Hyperkalemia 04/2022 - 12/2005
12	Hypertension (High Blood Pressure) 01/2018 - 07/2009
11	Diabetes Mellitus 03/2022 - 01/2015
10	Stroke (Strokes) 01/2022 - 10/2012
9	Diabetes Complications 07/2022 - 03/2013
8	Body Weight (Weight, Body) 12/2021 - 01/2008
8	Proteinuria 01/2021 - 03/2004
7	Fibrosis (Cirrhosis) 04/2022 - 11/2010
7	Heart Diseases (Heart Disease) 01/2021 - 08/2011
6	Weight Loss (Weight Reduction) 12/2021 - 11/2015
6	Atherosclerosis 01/2021 - 08/2011
6	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2021 - 10/2004
5	Obesity 01/2022 - 03/2017
5	Infections 01/2021 - 12/2019
4	Myocardial Infarction 01/2022 - 12/2018
3	Hypoglycemia (Reactive Hypoglycemia) 07/2022 - 03/2011
3	Neoplasms (Cancer) 01/2021 - 01/2017
3	Insulin Resistance 01/2020 - 01/2017
2	Hypertrophy 03/2022 - 03/2012
2	Overweight 01/2022 - 01/2022

Drug/Important Bio-Agent (IBA)

56	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2006
50	AlbuminsIBA 04/2022 - 05/2002
45	CreatinineIBA 04/2022 - 10/2004
26	dapagliflozinIBA 04/2022 - 01/2019
24	Glucose (Dextrose)FDA LinkGeneric 07/2022 - 01/2009
20	Liraglutide FDA Link 01/2022 - 04/2015
19	finerenoneIBA 06/2022 - 01/2014
16	Mineralocorticoid Receptor AntagonistsIBA 04/2022 - 01/2014
16	Sodium-Glucose Transporter 2 InhibitorsIBA 03/2022 - 12/2018
15	Antihypertensive Agents (Antihypertensives)IBA 01/2019 - 05/2002
15	Losartan (Cozaar)FDA LinkGeneric 01/2017 - 07/2002
13	SodiumIBA 03/2022 - 12/2018
13	Insulin (Novolin)FDA Link 01/2022 - 01/2008
12	Sodium-Glucose Transport ProteinsIBA 01/2022 - 12/2018
12	Irbesartan FDA LinkGeneric 01/2016 - 03/2004
11	pro-brain natriuretic peptide (1-76)IBA 09/2021 - 08/2011
11	CalciumIBA 01/2021 - 08/2011
10	Uric Acid (Urate)IBA 12/2021 - 07/2009
10	ProteomeIBA 01/2020 - 07/2008
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2010
9	Glucagon-Like Peptide 1 (GLP 1)IBA 08/2021 - 07/2015
9	CholesterolIBA 01/2021 - 03/2003
9	Angiotensin Receptor AntagonistsIBA 01/2019 - 07/2002
8	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 01/2020
8	Peptides (Polypeptides)IBA 01/2022 - 01/2008
7	Spironolactone (Aldactone)FDA LinkGeneric 03/2022 - 12/2005
7	Pharmaceutical PreparationsIBA 01/2022 - 01/2017
7	LipidsIBA 01/2022 - 02/2015
7	aliskiren FDA Link 10/2013 - 10/2009
6	AldosteroneIBA 04/2022 - 12/2005
6	PotassiumIBA 01/2022 - 12/2005
5	empagliflozinIBA 06/2022 - 11/2019
5	Urokinase Plasminogen Activator ReceptorsIBA 01/2022 - 06/2016
5	SymportersIBA 01/2022 - 05/2019
5	Angiotensin IIIBA 12/2021 - 08/2002
5	Biological ProductsIBA 11/2021 - 11/2011
5	Brain Natriuretic Peptide (Natrecor)FDA Link 09/2021 - 07/2010
5	Metformin (Glucophage)FDA LinkGeneric 08/2021 - 01/2008
5	Hemoglobins (Hemoglobin)IBA 01/2021 - 10/2004
5	C-Reactive ProteinIBA 01/2021 - 01/2013
5	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2019 - 05/2003
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019 - 09/2005
5	AdiponectinIBA 01/2016 - 08/2008
5	Vitamin D FDA LinkGeneric 10/2013 - 10/2010
5	Advanced Glycation End ProductsIBA 11/2011 - 12/2006
4	omega-Chloroacetophenone (Mace)IBA 01/2021 - 01/2020
4	Atrial Natriuretic Factor (ANF)IBA 10/2020 - 01/2017
4	CollagenIBA 10/2019 - 11/2010
4	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2019 - 09/2005
4	Connective Tissue Growth FactorIBA 01/2015 - 06/2005
4	Edetic Acid (EDTA)FDA Link 04/2008 - 08/2002
3	Blood Glucose (Blood Sugar)IBA 01/2022 - 01/2015
3	semaglutideIBA 01/2022 - 11/2020
3	trimethyloxamine (trimethylamine N-oxide)IBA 01/2021 - 01/2017
3	candesartanIBA 01/2021 - 01/2016
3	Glucagon-Like Peptide-1 ReceptorIBA 01/2021 - 07/2015
3	Triglycerides (Triacylglycerol)IBA 10/2020 - 01/2016
3	bardoxolone methylIBA 10/2019 - 03/2013
3	N 30IBA 01/2019 - 11/2009
3	Lipocalin-2IBA 11/2018 - 01/2011
3	ReninIBA 10/2013 - 11/2008
3	Fatty Acid-Binding ProteinsIBA 05/2011 - 09/2009
2	Immunoglobulins (Immunoglobulin)IBA 06/2022 - 01/2021

Therapy/Procedure

37	Therapeutics 06/2022 - 03/2004
10	Glycemic Control 07/2022 - 12/2006
4	Transplantation 01/2022 - 09/2004
3	Kidney Transplantation 12/2021 - 09/2012